Skip to main content
DRREDDY · Health Care · 2026-08-24

Dr Reddy's Laboratories Ltd

Stage 4 · wk 3In scan: Breakout WatchMARKET: WEAK RECOVERING · 2026-08-24
₹1,190
+1.30% today
₹99,127 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Visit company website →
P/E (TTM)
26.2
Forward 20.4
Earnings Growth (YoY)
-86.2%
Revenue -11.6%
ROE
+11.8%
Profit margin +12.8%
Dividend Yield
0.60%
P/B 2.9
vs 52W High
-13.5%
₹1,135.6 lo₹1,375.7 hi
13.5% below 52W high — failed near resistance
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 3
1w13w26w
Week 3 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-5.2%
200 DMA: ₹1,255.5 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.00x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
MA20 flat · -0.4% vs MA50 -3.9%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↓ Peaking
Stage 2%
48.9%
20d Δ
-1.5pp
1M return
+3.2%
3M return
+8.9%
Sector Stage-2 % · last 20 days
Sector has 84 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↑ Building
Stage 2%
50.8%
20d Δ
+1.3pp
1M return
+3.2%
3M return
+9.6%
Industry Stage-2 % · last 20 days
Industry has 59 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-30 → 2026-08-24
S2 21w
S2 22w
S2 14w
S2 16w
2023-05-302026-08-24
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 21w → S3 6w → S2 22w → S3 8w → S2 14w → S3 8w → S4 4w → S1 1w → S2 2w → S1 2w → S2 1w → S1 1w → S4 13w → S1 5w → S2 8w → S3 6w → S2 6w → S3 9w → S4 6w → S1 3w → S2 16w → S3 1w → S4 3w current
Total tracked: 166 weeks across 23 stage runs.
1M
+3.3%
3M
-10.6%
6M
-7.4%
YTD
-7.3%
1Y
-5.6%
Scan Membership
Breakout Watch
Latest: 2026-04-01
6 appearances in last 60 days. First seen: 2024-07-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-24S4
Wk 3 · Vol x
2026-08-21S4
Wk 3 · Vol x
2026-08-20S4
Wk 3 · Vol x
2026-08-19S4
Wk 2 · Vol x
2026-08-18S4
Wk 2 · Vol x
2026-08-17S4
Wk 2 · Vol x
2026-08-14S4
Wk 2 · Vol x
2026-08-13S4
Wk 2 · Vol x
2026-08-12S4
Wk 1 · Vol x
2026-08-11S4
Wk 1 · Vol x
2026-08-10S4
Wk 1 · Vol x
2026-08-07S4
Wk 1 · Vol x
Sector Peers — Stage 2All →
MARKSANS
wk 14 · -2.7% from hi
9.8
ALIVUS
wk 20 · -2.3% from hi
9.4
MOREPENLAB
wk 10 · -1.3% from hi
9.2
NEULANDLAB
wk 13 · -3.2% from hi
9.0
ANTHEM
wk 14 · -1.6% from hi
8.9
Moving averages & range
50 DMA
₹1,234.8
200 DMA
₹1,255.5
52W High
₹1,375.7
52W Low
₹1,135.6
5D Low
₹1,170
Resistance levels (recent highs)
20d High
₹1,206
60d High
₹1,375.7
120d High
₹1,375.7
250d High
₹1,375.7
Next resistance
+1.3%
to 20d High

All analytics based on EOD data. Data as of 2026-08-24. Past data patterns are not indicative of future results. This page is a data analytics tool only.